Categories: ChemicalDeliveryDevelopmentDrugMedTechProduct
Flamel Technologies SA is listed on the NASDAQ [FLML] and is a leading drug delivery company focused on the goal of developing safer, more efficacious formulations of drugs to tackle unmet medical needs. Their product development pipeline includes biological and chemical drugs formulated with their proprietary platforms, Medusa® and Micropump®.
Investors 1
Mentions in press and media 3
| Date | Title | Description |
| 10.09.2024 | MRM Health appoints Grégoire Franoux as Chief Business Officer and adds Ron Robison to its Board of Directors | GHENT, Belgium, September 10, 2024 – MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced the appointment of Grégoire Franoux, M.B.A., to ... |
| 15.10.2012 | Specialty pharmaceutical maker raising $7.7 million for safer, longer-lasting aspirin | Location: New Haven, Connecticut.
Solution/product: Using technology licensed from Yale University and Flamel Technologies, New Haven Pharmaceuticals develops controlled-release specialty pharmaceuticals. Its lead candidate, a once-daily, 2... |
| - | Specialty pharmaceutical maker raising $7.7 million for safer, longer-lasting aspirin | Reducing the side effects and improving compliance of the millions of people who take aspirin regularly is the goal of a pharmaceutical company raising up to $7.7 million in anticipation of a 2013 NDA filing.
Company name: New Haven Pharmac... |
Reviews 0
